ALT5 Sigma Corporation

Equities

ALTS

US47089W1045

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 16/07/2024 BST			5-day change	1st Jan Change
2.26 ^USD	+8.65%		+18.32%	+307.21%

07-10	Sector Update: Health Care Stocks Higher Late Afternoon	MT
07-10	Sector Update: Health Care Stocks Advance in Afternoon Trading	MT

JanOne Inc. Appoints Nicholas E. Goeders to its Scientific Advisory Board

June 15, 2021 at 03:15 pm

JanOne Inc. announced the appointment of Nicholas E. Goeders, Ph.D. to its Scientific Advisory Board. Goeders is professor and head of the Department of Pharmacology, Toxicology and Neuroscience at Louisiana State University (LSU) Health Sciences Center Shreveport, where he has been a member of the faculty since 1985. He is also a co-founder of Embera NeuroTherapeutics Inc., developer of a novel pharmacotherapy treatment for substance use disorders that is based on results from his research on stress and addiction.

Latest news about ALT5 Sigma Corporation

Sector Update: Health Care Stocks Higher Late Afternoon	07-10	MT
Sector Update: Health Care Stocks Advance in Afternoon Trading	07-10	MT
JanOne Approves Strategic Review of Biotech Assets, ALT5 Sigma Will Be Core Focus; Shares Rise Pre-Bell	07-10	MT
JanOne Inc.(NasdaqCM:JAN) added to Russell 3000E Value Index	06-30	CI
JanOne Inc.(NasdaqCM:JAN) added to Russell 3000E Index	06-30	CI
JanOne Inc.(NasdaqCM:JAN) added to Russell Microcap Index	06-30	CI
JanOne Inc.(NasdaqCM:JAN) added to Russell Microcap Value Index	06-30	CI
Exchange-Traded Funds, Equity Futures Tread Water Pre-Bell Friday Amid Waning September Rate Cut Hopes	05-17	MT
JanOne Closes Acquisition of Blockchain Fintech Firm -- Shares Fall After Hours	05-16	MT
JanOne Inc. completed the acquisition of Alt 5 Sigma Inc.	05-14	CI
JanOne to Acquire ALT 5 Sigma	05-10	MT
JanOne Inc. executed a Definitive Agreement to acquire Alt 5 Sigma Inc.	05-09	CI
JanOne Inc. Reports Earnings Results for the First Quarter Ended March 30, 2024	05-03	CI
JanOne Files Prospectus for $100 Million Mixed Shelf Offering	04-18	MT
North American Morning Briefing : Stock Futures -2-	04-15	DJ
JanOne Inc. Reports Earnings Results for the Full Year Ended December 30, 2023	04-08	CI
JanOne Inc. announced that it expects to receive $0.6 million in funding	02-22	CI
JanOne Inc. announced that it expects to receive $0.3 million in funding from Live Ventures Incorporated	02-06	CI
JanOne Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Wall Street Set to Open Higher Thursday as Jobless Claims Fall, Ahead of Powell Speech	11-09	MT
Investors Await Jobless Claims Report, Powell Speech as US Futures Remain Flat in Thursday Trading	11-09	MT
Top Premarket Gainers	11-09	MT
JanOne Raises $790,000 in Registered Direct Offering of Shares, Private Placement of Warrants	23/08/23	MT
JanOne Prices Registered Direct Offering, Announces Concurrent Private Placement	21/08/23	MT
JanOne Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 01, 2023	15/08/23	CI

Chart ALT5 Sigma Corporation

Duration

Period

More charts

Company Profile

JanOne Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, acquiring, licensing, developing, partnering, and commercializing novel, no-opioid, and non-addictive therapies to address the large, unmet medical need for the treatment of pain and addiction. Its drug candidate, JAN101, is a patented oral, sustained-release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities, such as those with vascular complications of diabetes or Peripheral Artery Disease (PAD) and treats pain. Its drug candidate is a treatment for Peripheral Artery Disease. The Company operates through the Biotechnology segment, which is focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Company is also engaged in providing blockchain-powered technologies through its two platforms: ALT 5 Pay and ALT 5 Prime.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ALT5 SIGMA CORPORATION	+307.21%	26.38M
MODERNA, INC.	+25.83%	47.96B
LONZA GROUP AG	+45.77%	41.47B
IQVIA HOLDINGS INC.	+0.69%	42.45B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	31.6B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.63B
CELLTRION, INC.	-6.35%	28.03B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.56B
MEDPACE HOLDINGS, INC.	+49.18%	14.14B
BIO-TECHNE CORPORATION	+3.45%	12.58B

Other Biotechnology & Medical Research